14 November 2025 - Sarepta Therapeutics today announced an update to the prescribing information for Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy.

As previously disclosed, the Elevidys label now includes several key updates, including. a boxed warning for the risk of acute serious liver injury and acute liver failure.

Read Sarepta Therapeutics press release